Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Acotec Scientific Holdings Limited ( (HK:6669) ).
Acotec Scientific reported strong growth for 2025, with revenue rising 20.7% to RMB644.6 million and profit for the year surging 128.0% to RMB119.2 million, driven by diversified product revenue and improved operational efficiency. Core products generated RMB319.0 million, while venous intervention, vascular access and other products jumped 51.1% to RMB322.9 million, underscoring a shift toward multiple growth pillars.
The company’s R&D-led strategy delivered 11 new product approvals from Chinese regulators and the U.S. FDA, expanding its presence in five therapeutic areas and reinforcing its position in drug-coated balloon and neurointervention markets. Notable launches included vertebral artery and sirolimus-coated coronary balloons and new thrombus aspiration devices, which strengthened its competitive edge and broadened commercialization opportunities in both domestic and international markets.
The most recent analyst rating on (HK:6669) stock is a Hold with a HK$15.00 price target. To see the full list of analyst forecasts on Acotec Scientific Holdings Limited stock, see the HK:6669 Stock Forecast page.
More about Acotec Scientific Holdings Limited
Acotec Scientific Holdings Limited is a China-based medical device company specializing in interventional products for vascular surgery, cardiology, nephrology, neurology and oncology. Its portfolio spans drug-coated balloons, ablation systems and thrombus aspiration solutions, and it markets these products across Mainland China and increasingly in overseas markets.
Average Trading Volume: 317,329
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.66B
See more data about 6669 stock on TipRanks’ Stock Analysis page.